These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30628161)

  • 21. Ring-fencing a budget for cancer drugs: is it fair?
    Graham J; Cassidy J; Hughes D; Duerden M
    J R Coll Physicians Edinb; 2011 Sep; 41(3):224-8. PubMed ID: 21949920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cancer in health economics].
    Delande G
    Bull Cancer Radiother; 1994; 81(2):91-8. PubMed ID: 7702899
    [No Abstract]   [Full Text] [Related]  

  • 23. Why clinical oncologists should talk about the price of cancer drugs.
    Berlinger N
    Virtual Mentor; 2013 Aug; 15(8):677-80. PubMed ID: 23937783
    [No Abstract]   [Full Text] [Related]  

  • 24. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.
    McCullagh L; Schmitz S; Barry M; Walsh C
    Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Innovative therapy, early and cost-benefit assessment].
    Dierks C
    Onkologie; 2012; 35 Suppl 2():7. PubMed ID: 22517064
    [No Abstract]   [Full Text] [Related]  

  • 26. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
    Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
    J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
    Morrell L; Wordsworth S; Fu H; Rees S; Barker R
    BMC Health Serv Res; 2017 Aug; 17(1):613. PubMed ID: 28854927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationing in cancer treatment: is the identification of essential cytotoxic drugs feasible?
    Sessa C
    Ann Oncol; 1999 Apr; 10(4):373-4. PubMed ID: 10370776
    [No Abstract]   [Full Text] [Related]  

  • 30. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
    Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
    J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
    [No Abstract]   [Full Text] [Related]  

  • 31. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.
    Tannock IF; Ratain MJ; Goldstein DA; Lichter AS; Rosner GL; Saltz LB
    J Clin Oncol; 2021 Mar; 39(9):950-955. PubMed ID: 33555940
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cost/benefit analysis of cancer drugs].
    Jordan B
    Med Sci (Paris); 2020 Nov; 36(11):1095-1097. PubMed ID: 33151876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Economic effects of "molecular" medicine].
    Riemann JF
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1740. PubMed ID: 17713881
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of cancer in adolescents and young adults: is affordability a concern?
    Gafni A
    Cancer; 2011 May; 117(10 Suppl):2258-61. PubMed ID: 21523743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient access schemes for high-cost cancer medicines.
    Williamson S
    Lancet Oncol; 2010 Feb; 11(2):111-2. PubMed ID: 20152762
    [No Abstract]   [Full Text] [Related]  

  • 36. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 38. New "managed access" process for Cancer Drugs Fund to go ahead, NHS England confirms.
    Mayor S
    BMJ; 2016 Feb; 352():i1208. PubMed ID: 26926879
    [No Abstract]   [Full Text] [Related]  

  • 39. US Cancer Care System Ill-Equipped to Deliver New Advances to Patients.
    Rappaport M
    J Oncol Pract; 2016 May; 12(5):397. PubMed ID: 27170686
    [No Abstract]   [Full Text] [Related]  

  • 40. Economic and quality of life outcomes: the four-step pharmacoeconomic research model.
    Arikian SR; Suver J; Einarson T; Doyle J
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):33-6. PubMed ID: 8608054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.